Full Text (PDF)
Review Article

Role of Cardiac Evaluation in Young Competitive Athletes with Physiological Hypertrophic Cardiomyopathy and Bradycardia: Analytical Review

Charles O. Masese, Faith Chebet, Timothy V, Anthony Gikonyo, Premanand Ponoth, Dan Gikonyo

Author Information

Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. 


Journal of Cardiovascular Medicine and Surgery 10(3-4):p 75-78, July -Dec. 2024. | DOI: http://dx.doi.org/10.21088/jcms.2454.7123.103424.3

How Cite This Article:

Masese CO, Chebet F, Wachira T, et al. Role of cardiac evaluation in young competitive athletes with physiological hypertrophic cardiomyopathy and bradycardia: analytical review. J Cardiovasc Med Surg. 2024;10(3-4):75-78.

Timeline

Received : June 26, 2024         Accepted : August 17, 2024          Published : December 29, 2024

Abstract

Background: Athletes hearts are generally larger and stronger than those of non-athletes due to their physical demand Cardiomyopathy of their sports. This is due to physiological adaptation to regular intense exercise. Hypertrophic cardiomyopathy (HCM) is a cardiac disorder characterized by thickening of the heart muscle, which can lead to heart failure, arrhythmias, and sudden cardiac death. Athletes with HCM may be at increased risk of adverse cardiac events due to the combination of exercise-induced changes in heart function and the underlying cardiac abnormalities. Bradycardia typically is a heart rate of less than 60 beats per minute. Athletes may develop bradycardia as a result of their training, adaptation of the heart in response to regular physical activity" commonly known as athlete's heart."Athletes with HCM develop an enlarged heart, which can be mistaken for" athlete's heart. Objectives: To provide an overview of the prevalence, diagnosis, and management of HCM in athletes. Method: A case study of 25-year-old who presented with shortness of breath, chest pains, and palpitations on exertion. He had an electrocardiogram and echocardiogram with features of HCM; however, the LV diastolic function was normal and cardiopulmonary exercise testing revealed high peak oxygen consumption in keeping it with a physiological left ventricular hypertrophy. Lifestyle modifications, by reducing the intensity of exercise to help manage symptoms and minimize the risk of complications were implemented. Medications to improve heart function. With these, there was a complete change on his ECG and Echocardiography, thereafter indicating a physiological LVH rather than HCM. Conclusion: HCM is the most common cause of sudden cardiac death (SCD) in young athletes, accounting for up to 36% of cases. Prevalence of HCM in athletes is estimated to be around 0.2%, which is higher than that in the general population. Not all athletes with HCM are at equal risk of SCD, and risk stratification is an essential part of management.


References

  • 1.   Pelliccia, A., Maron, B. J., & Corrado, D. (2018). The athlete's heart: an update of the 2003 statement. European Heart Journal, 39(17), 1463-1469.
  • 2.   Sharma, S., Drezner, J. A., Baggish, A., Papadakis, M., Wilson, M. G., Prutkin, J. M., ... & Ackerman, M. J. (2017). International recommendations for electrocardiographic interpretation in athletes. Journal of the American College of Cardiology, 69(8), 1057-1075.
  • 3.   Maron B. J. (2009). Distinguishing hypertrophic cardiomyopathy from athlete's heart physiological remodeling: clinical significance, diagnostic strategies and implications for preparticipation screening. British journal of sports medicine.
  • 4.   Paterick, T. E., Tajik, A. J., & Schutt, R. C. (2015). The athlete’s heart: a contemporary appraisal of the “Morganroth hypothesis”. Mayo Clinic Proceedings, 90(5), 683-690.
  • 5.   Munim A, Ethan J, Audhavi S, Martin S (2020). The Role of Physical Deconditioning in Distinguishing Hypertrophic Cardiomyopathy from Athletes Heart. American heart association

Data Sharing Statement

There are no additional data available.

Funding

This research received no funding.

Author Contributions

All authors contributed significantly to the work and approve its publication.

Ethics Declaration

This article does not involve any human or animal subjects, and therefore does not require ethics approval

Acknowledgements

Information Not Provided

Conflicts of Interest

No conflicts of interest in this work.


About this article


Cite this article

Masese CO, Chebet F, Wachira T, et al. Role of cardiac evaluation in young competitive athletes with physiological hypertrophic cardiomyopathy and bradycardia: analytical review. J Cardiovasc Med Surg. 2024;10(3-4):75-78.


Licence:

Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. 


Received Accepted Published
June 26, 2024 August 17, 2024 December 29, 2024

DOI: http://dx.doi.org/10.21088/jcms.2454.7123.103424.3

Keywords

Hypertrophic CardiomyopathyBradycardiaAthlete Cardiac Screening

Article Level Metrics

Last Updated

Monday 22 June 2026, 11:09:25 (IST)


681

Accesses

2
121
00

Citations


NA
NA
NA

Download citation


Article Keywords


Keyword Highlighting

Highlight selected keywords in the article text.


Timeline


Received June 26, 2024
Accepted August 17, 2024
Published December 29, 2024

licence


Attribution-Non-commercial 4.0 International (CC BY-NC 4.0)

This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. 


Access this article



Share